CURRICULU M VITAE (January, 2025)
`Rudolph M
`odesto Navari, M.D., Ph.D., F.A.C.P
`.
`CURRENT P
`OSITION: Hematologist Oncologist
`4518 Crown Point Lane
`Birmingham, AL 35117
`T: 574 261 8385– Fax: (205) 285 5271
`E-mail: rmnav ari@gmail.com
`EDUCATI
`ON:
`1966 B.S
`., Chemical Engineering, University of Notre Dame
`1968 M.S., Chemical Engineering, University of Virginia
`1970 Ph.D., Chemical Engineering, University of Virginia
`1977 M.D., Medical College of Virginia
`PROF
`ESSIONAL EXPERIENCE:
`1968 - 1969 Ins
`tructor in Chemical Engineering, University of Virginia
`1970 - 1971 Ins
`tructor, American Institute of Chemical Engineers
`Continuing Education Program, "Surface Chemistry"
`1970 - 1971 Res
`earch Scientist, Research and Development Center,
`Union Camp Corporation, Princeton, New Jersey
`1971 - 1973 As
`sistant Professor of Chemistry,
`Hollins College
`Roanoke, Virginia
`1974 - 1977 Res
`earch Associate, Department of Medicine,
`Medical College of Virginia
`Richmond, Virginia
`1977 - 1978 Int
`ern, Department of Internal Medicine,
`University of Alabama, Birmingham
`1978 - 1980 Re
`sident, Department of Internal Medicine,
`University of Alabama, Birmingham
`1980 - 1981 Chi
`ef Resident and Instructor in Medicine,
`University of Alabama, Birmingham
`HELSINN EXHIBIT 2044
`Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
`IPR2025-00948
`Page 1 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 2
`
`1981 - 1983 Fellow, Division of Medical Oncology, Department of Medicine
` University of Washington and the Fred Hutchinson Cancer Research Center,
`Seattle, Washington
`
`1983 – 1998 Staff Physician, Internal Medicine and Medical Oncology,
`Simon-Williamson Clinic, Birmingham, Alabama
`Baptist Medical Center - Princeton, Birmingham, Alabama
`Bessemer Carraway Medical Center, Bessemer, Alabama
`
`1983- 1998 Clinical Instructor, Medical Residency Program
` Baptist Health Care System, Birmingham, Al
`
`1987 – 1998 Advisory Council, College of Science
`University of Notre Dame
`(Chairman, 1991 - 1992)
`
`1989 - 1992 Chairman, Department of Medicine
`Simon-Williamson Clinic, P.A.
`Birmingham, Alabama
`
`1989 – 1998 Director, Bone Marrow Transplantation Program
`Baptist Medical Center Princeton
`Birmingham, Alabama
`
`1990 – 1998 Chairman, Comprehensive Cancer Committee
`Gordon L. Ross Cancer Center
`Baptist Medical Center - Princeton
`
`1992 – 1998 Medical Director, Hospice Program
`Bessemer Carraway Medical Center
`
`1992 - 1995 President, Simon- Williamson Clinic, P.C.
`Birmingham, Alabama
`
`1993 – 1998 Chairman, Cancer Committee
`Bessemer Carraway Medical Center
`
`1993 – 1998 Member, Joint Policy Board
`PhyCor of Birmingham
`
`
`PROFESSSIONAL EXPERIENCE (cont.)
`Page 2 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 3
`
`
`1995 - 1996 Instructor, Alabama School of Mathematics and Science
` Birmingham, Alabama
`
`1997- 1999 Chairman, Oncology Care Management Council,
` PhyCor, Inc., Nashville, Tennessee
`
`1998 – 1999 Fellow, MacLean Center for Clinical Medical Ethics,
` University of Chicago School of Medicine
`
`1999 – 2001, Hematologist – Oncologist
`2007 – 2014 South Bend Clinic
`
`1999 – 2005 Director, Walther Cancer Research Center
` Professiona l Specialist, Department of Pre-Professional Studies
` College of Science
` University of Notre Dame
`
`2000 – 2005 Associate Dean, College of Science
` University of Notre Dame
`
`2001 – 2006 Hematologist – Oncologist
` Northern Indiana Oncology Associates
` South Bend, IN
`
`2005 – 2009 Director, Walther Cancer Research Center
` Adjunct Professor of Biochemistry
` Department of Chemistry and Biochemistry
` University of Notre Dame
`
`2005 – 2011 Professor of Medicine
` Assistant Dean and Director
` Indiana University School of Medicine South Bend
` Adjunct Professor of Biochemistry
` Department of Chemistry and Biochemistry
`University of Notre Dame
`
`2010 – 2013 Clinical Director, Harper Cancer Research Institute
` Indiana University School of Medicine South Bend
`
`
`
`Page 3 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 4
`
`2012 – 2014 Professor of Medicine
` Associate Dean and Director
` Indiana University School of Medicine South Bend
` Adjunct Professor of Biochemistry
` Department of Chemistry and Biochemistry
`University of Notre Dame
`
`2013- 2014 Medical Director
` Navari Student Outreach Clinic
` Indiana University School of Medicine South Bend
`
`2014 – 2015 Director, Cancer Care Program
` Eastern Europe
` World Health Organization
`
`2014 – 2015 Clinical Professor of Medicine
` Indiana University School of Medicine South Bend
`
`2014 - Present President, South Bend Medical Services Corporation
` South Bend, IN
`
`2015 – 2016 Director, Cancer Care Program
` Central and South America
` World Health Organization
`
`2016 – 2020 Professor of Medicine
` Division of Hematology – Oncology
` University of Alabama Birmingham (UAB) School of Medicine
`
`2017 – 2020 Hematologist – Oncologist
` Birmingham VA Medical Center
`
`2017 – 2020 Senior Scientist, Experimental Therapeutics Program
` UAB Comprehensive Cancer Center
`
`2017 – 2020 Clinical Skills Scholar
` University of Alabama Birmingham School of Medicine
`
`2020 – Present Executive Director
` Cancer Care Program, Central and South America
` World Health Organization
`
`Page 4 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 5
`
`2020 – 2022 Hematologist Oncologist
`Simon Williamson Clinic
` Birmingham, AL 35211
`
`2020-2022 Locums Coverage, Monthly Weekend Coverage
` Oncology Associates of West Alabama
` DCH Hospital. Tuscaloosa, AL
`
`1/2023 – 12/2023 Locums Coverage
` Cos Bay Cancer Center
` Cos Bay, Oregon
`
`1/2024 – Present Locums Coverage
` Hematology Oncology Associates of Alabama
` Gadsden, AL
`
`8/2024 – Present Hematologist Oncologist
` Oncology Clinic
` Cooper Green Health – UAB
` Birmingham, AL
`
`
`BOARD CERTIFICATION AND LICENSING:
`
`1978 Diplomate, National Board of Medical Examiners
`1978 State of Alabama Medical License (#8424)
`1981 Diplomate, American Board of Internal Medicine
`1981 State of Washington Medical License
`1983 Diplomate, Subspecialty Board of Medical Oncology
`1998 State of Indiana Medical License
`2016 State of Mississippi Medical License
`2020 State of Missouri Medical License
`
`PROFESSIONAL AND HONORARY SOCIETIES:
`
`1974 - Present Alpha Sigma Chi (Leadership Honorary)
`American Association for Advancement of Science, Member
`American College of Physicians, Member
`1977 - Present American Federation for Clinical Research, Member
`American Institute of Chemical Engineers, Associate Member
`American Chemical Society, Member
`1968 - Present Sigma Xi (Research Honorary), Member
`Page 5 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 6
`
`1972 - 1973 President, Hollins College Sigma Xi Club
`1966 Tau Beta Pi (Engineering Honorary), Member
` Virginia Academy of Science, Member
`1983 – Present Alabama Society of Clinical Oncology
` (President, 1986-88)
`1983 – Present American Society of Clinical Oncology, Member
`
`HONORS
`
`1966 Cum Laude Graduate, University of Notre Dame
`1966 - 1969 NDEA Title IV Fellowship, University of Virginia,
`1969 - 1970 Ethyl Corporation Fellowship, University of Virginia,
`1974 A. D. Williams Research Fellowship, Medical College of Virginia
`1976 L. Beverly Chaney Leadership Award, Medical College of Virginia
`1977 School of Medicine Research Prize - First Place, Medical College of Virginia
`1977 - 1978 Ben Friedman Award - Excellence in Teaching by an Intern,
`University of Alabama, Birmingham
`1979 - 1980 Ben Friedman Award - Excellence in Teaching by a Resident,
`University of Alabama, Birmingham
`1981 - 1982 Clinical Fellowship, American Cancer Society
`1985 Outstanding Physician Award for Clinical Instruction ,
`Baptist Medical Center - Princeton
`1997 Fellow, American College of Physicians
`2006 Fellow, John J. Reilly Center for Science, Technology, and Values,
` University of Notre Dame
`2009 Emil T. Hofmann Lecturer, University of Notre Dame
`2014 Sagamore of the Wabash Award, Leadership and Service
` Governor Michael Pence, State of Indiana
`2014 Navari -Harper Scholarship
` Indiana University School of Medicine South Bend
`2014 Navari Student Outreach Clinic
` Indiana University School of Medicine South Bend
`2014 Honoree, 2014 Medicine Ball
` Indiana University School of Medicine South Bend
`2015 Token of Appreciation from Medical Students Award
` University of Michigan Medical School
`2017 Clinical Skills Scholar
` University of Alabama School of Medicine
`
`
`
`EDITORIAL BOARDS
`Page 6 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 7
`
`
`2002 – Present Current Drug Targets, Associate Editor
`2004 - 2014 National Cancer Institute Supportive Care Editorial Board
`2016- Present Expert Review of Quality of Life in Cancer Care
`2016- Present Cancer Management and Research, Associate Editor
`
`PUBLICATIONS:
`
` 1. Navari, R.M. and Gainer, J.L.: Prediction of the sigma effect in blood flow, 1968.
`Biorheology 5: 237-239.
`
` 2. Navari, R.M., Gainer, J.L., and Updike, O.L.: Blood flow modeling with microcapsular
`suspensions, 1969. Ind. Eng. Chem. Fund 8: 615-624.
`
` 3. Navari, R.M., Gainer, J.L., and Hall, K.R.: Effect of plasma constituents on oxygen
`diffusivity, 1970. In: Blood Oxygenation, Hershey, D. (ed.). New York: Plenum Press, pp
`243-261.
`
` 4. Navari, R.M., Gainer, J.L., and Hall, K.R.: A predictive theory for diffusion in polymer and
` protein solutions, 1971. Am. Inst. Chem. Eng. J. 10: 1028-1036.
`
` 5. Navari, R.M., Gainer. J.L., and Hall, K.R.: Transport in human plasma, 1971. Aerospace
`Med. 42: 1123-1125.
`
`6. Navari, R.M. and Gainer, J.L.: Effect of red cell deformability on blood viscosity, 1972.
`Rheology of Biological Systems, Gabelnick, H. and Litt, M. (eds), Philadelphia: C.C.
`Thomas, Chap. 3.
`
`7. Navari, R.M.: Hematology for undergraduates, 1972. J. College Science Teaching 2: 26-33.
`
`8. Bryant, S.C. and Navari, R.M.: Effect of plasma proteins on oxygen diffusion in the
`pulmonary capillaries, 1974. Microvascular Res. 7: 1-11.
`
` 9. Navari, R.M.: Laboratory experiments using nicotine, 1974. J. Chem. Education 51: 748-
`750.
`
`10. Navari, R.M. and Prodouz, T.N.: Effects of vitamins and E on rat tissue lipids, 1975.
`Nutrition Reports International 11: 17-28.
`
`11. Rosenblum, W.I., Navari, R.M., Levasseur, J.R., and Patterson, J.L., Jr.: In vitro depression
`of tissue oxygen uptake by liquid fluorocarbon prepared as artificial blood, 1977. Proc. Soc.
`Exp. Med. Biol. 154: 346-350
`Page 7 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 8
`
`
`12. Navari, R.M., Rosenblum, W.I., Kontos, H.A., and Patterson, J.L., Jr.: Mass transfer
`properties of gases in fluorocarbon emulsions, 1977. Res. Exp. Med. 170: 169-180.
`
`13. Navari, R.M., Rosenblum, W.I., Kontos, H.A., Levasseur, J.E., and Patterson, J.L., Jr.:
`Effects of perfluorochemical emulsions prepared as artificial blood on the in vitro oxygen
`consumption of rat pulmonary bronchioles, 1977. Proceedings of Symposium on Research
`on Perfluoro- chemicals in Medicine and Biology, Novakova, V. (ed.). Stockholm :
`Karolinska Institute.
`
`14. Navari, R.M. and Patterson, J.L., Jr.: Inhibition of rat bronchiolar oxygen consumption by
`plasma proteins, 1978. J. Appl. Physiol. Respirat. Environ. Exercise Physiol. 44: 659-664.
`
`15. Navari, R.M., Wei, E.P., Kontos, J.A., and Patterson, J.L., Jr.: Comparison of the open skull
`and cranial window preparations in the study of the cerebral microcirculation, 1978.
`Microvascular Res. 16: 304-315.
`
`16. Kontos, J.A., Wei, E.P., Navari, R.M., Levasseur, J.E., Rosenblum, W. I., and Patterson,
`J.L., Jr.: Responses of cerebral arteries and arterioles to acute hypotension and hypertension,
`1978. Am. J. Physiol. 234: H371-H383.
`
`17. Kontos, H.A., Wei, E.P., Raper, A.J., Rosenblum, W.I., Navari, R.M., and Patterson, J.L.,
` Jr.: Role of tissue hypoxia in local regulation of cerebral microcirculation, 1978.
`Am. J. Physiol. 234: H582-H591.
`18. Navari, R.M., Wei, E.P., Kontos, H.A., and Patterson, J.L., Jr.: Oxygen consumption of pial
`arterioles, 1979. Am. J. Physiol. 236: H151-H156.
`
`19. Wei, E.P., Dietrich, W.D., Povlishock, J.T., Navari, R.M., and Kontos, H.A.:
`Functional,morphologic and metabolic abnormalities of the cerebral microcirculation after
`concussive brain injury in cats, 1980. Circ. Res. 46: 37-47.
`
`20. Kontos, H.A., Wei, E.P., Dietrich, W.D., Navari, R.M., Povlishock, J.T., Ghatak, N.R., Ellis,
`E.F., and Patterson, J.L., Jr.: Mechanism of cerebral arteriolar abnormalities after acute
`hypertension, 1981. Am. J. Physiol. 240: H511-H527.
`
`21. Navari, R.M., Ploth, D.W., and Tatum, R.K.: Renal adenocarcinoma associated with multiple
`simple cysts, 1981. JAMA 246: 1808-1809.
`
`22. Navari, R.M. and Sheehy, T.W.: Routine endoscopy in upper gastrointestinal bleeding,
`1982. N. Engl. J. Med. 306: 870.
`
`23. Navari, R.M., Sheehy, T.W., McLean, B.K., and Sutton, F.D.: The peripheral blood in heat
`Page 8 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 9
`
`stroke, 1983. Alabama J. Med Sci 20: 137-140.
`
`24. Navari, R.M., Carter, J., and Hillman, R.S.: Bone marrow necrosis in acute leukemia, 1983.
` Acta Haemat. 69: 158-163.
`
`25. Navari, R.M., Sharma, P., Deeg, H.J., McDonald, G.B., and Thomas, E.D.: Pneumatosis
`cystoides intestinalis following allogeneic marrow transplantation, 1983. Clin. Transplant.
`Proc. 15: 1720-1724.
`
`26. Navari, R.M., Sullivan, K.M., Springmeyer, S.C., Siegel, M.C., Meyers, J.D., Buckner, C.D.,
`Sanders, J.E., Stewart, P.S., Clift, R.A., Fefer, A., Storb, R., and Thomas E.D.:
`Mycobacterial infections in marrow transplant patients, 1983. Transplantation, 36: 509-513.
`
`27. Navari, R.M., Buckner, C.D., Clift, R.A., and Coleman, K.M.: Bone marrow transplantation,
`1984. Laboratory Medicine, 15: 245-250.
`
`28. Navari, R.M., Buckner, C.D., Clift, R.A., Storb, R., Sanders, J.E., Stewart P., Sullivan K.M.,
`Williams, B., Counts, G.W., Meyers, J.D., and Thomas, E.D.: Prophylaxis of infection in
`patients with aplastic anemia receiving allogeneic marrow transplants, 1984. Am. J. Med.,
`76: 564-572.
`29. Sheehy, T.W. and Navari, R.M: Hypothermia, 1984. Alabama J. Med. Sci. 21: 374 - 381.
`
`30. Clift, R.A., Buckner, C.D., and Navari, R.M.: Marrow Transplantation, 1985. In:
`Comprehensive Textbook of Oncology, Moossa, A.R., Robson, M.C., and Schimpff, S.C.
`(eds.), Baltimore: Williams and Wilkins, Ch. 27.
`
`31. Navari, R.M. and Sheehy, T.W.: Hypothermia, 1986. In: The Practice of Geriatrics.
`Calkins, E., Davis, P.J., Ford, A.M. (eds.) Philadelphia: W.B. Saunders Company, Ch. 28.
`
`32. Witherspoon, R.P., Navari, R.M., Storb, R., Sullivan, K.M., Doney, K., Beatty, P., Lum,
`L.G., and Thomas, E.D.: Treatment of Marrow Graft Recipients with Thymopentin, 1987.
`Bone Marrow Transplantation, 1: 365-371.
`
`33. Navari, R.M.: High Dose Chemotherapy and Autologous Bone Marrow Infusion for
`Malignancies Refractory to Conventional Treatment, 1987. Bulletin of Clinical Services -
`Baptist Medical Center Princeton, 1(1): 15-21.
`
`34. Navari, R.M.: Effective Antiemetic Therapy for the Control of Chemotherapy-Induced
`Emesis, 1987: Bulletin of Clinical Services - Baptist Medical Center Princeton, 1(2): 15-21.
`
`35. Navari, R.M.: Comparison of Intermittent and Continuous Infusion Metoclopramide for the
`Control of Acute Nausea in Patients Receiving Cisplatin Chemotherapy, 1989. J. Clinical
`Page 9 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 10
`
`Oncology, 7: 943-946.
`
`36. Navari, R.M.: Primary Central Nervous System Malignant Lymphoma, 1989: Bulletin of
`Clinical Services - Baptist Medical Center Princeton 3(1): 2-9.
`
`37. Navari, R.M.: The Ethics of Organ Transplantation, 1989. Notre Dame Science Quarterly,
`27: 17-21.
`
`38. Santen, R.J., Demers, L.M., Lynch, J., Harvey, H., Lipton, A., Mulagha, M., Hanagan, J.,
`Garber, J.E., Henderson, I.C., Navari, R.M. and Miller, A.A.: Specificity of Low Dose
`Fadrozole Hydrochloride (CGS 16949A) as an Aromatase Inhibitor. J. Clin. Endocrinol .
`Metab 73: 99-106, 1991.
`
`39. Beck,T.M.,Hesketh,P.J., Madajewicz, S., Navari,R.M., Pendergrass, K., Lester, E.P.,Kish,
`J.A.,Murphy, W.K., Hainsworth, J.D., Gandara, D.R., Bricker, L.J., Keller, A.M., Mortimer,
`J., Galvin, D.V.,House, K.W. and Bryson, J.C.: Stratified, Randomized, Double -Blind
`Comparison of Intravenous Ondansetron Administered as a Multiple-Dose Regimen Versus
`Two Single-Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting. J.
`Clin. Oncol. 10: 1969-1975, 1992.
`
`40. Richards, E.W., Long, C.L., Nelson, K.M., Pinkston, J.A., Navari, R.M., Geiger, J.W.,
`Gandy, R.E., Blakemore, W.S.: Glucose Metabolism in Advanced Lung Cancer Patients.
`Nutrition 8: 245-251, 1992.
`
`41. Richards, E.W., Long, C.L., Nelson, K.M., Tohver, O.K., Pinkston, J.A., Navari, R.M. and
`Blakemore, W.S.: Protein Turnover in Advanced Lung Cancer Patients. Metabolism, 42:
`291-296, 1993.
`
`42. Navari, R.M., Province, W.S., Perrine, G.M., Kilgore, J.R.: Comparison of Intermittent
`Ondansetron Versus Continuous Infusion Metoclopramide Used with Standard Combination
`Antiemetics in Control of Acute Nausea Induced by Cisplatin Chemotherapy. Cancer, 72:
`583-586, 1993.
`
`43. Navari, R.M., Kaplan, H.G., Grant, R.J., Grunberg, S.M., Palmer, R., Fitts, D.: Efficacy and
`Safety of Granisetron, A Selective 5 -Hydroxytryptamine - 3 Receptor Antagonist, in the
`Prevention of Nausea and Vomiting Induced by High Dose Cisplatin. J. Clin. Oncol., 12:
`2204-2210, 1994.
`
`44. Gucalp, R., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R.M., Ahmann, F.,
`Zelenakas, K., Hefferman, M., Knight, R.D.: Treatment of Cancer Associated
`Hypercalcemia. Arch Intern Med., 154: 1935-44, 1994.
`
`Page 10 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 11
`
`45. Navari, R.M., Gandara, D., Hesketh, P., et al: A Comparative Clinical Trial of Granisetron
`and Ondansetron in the Prophylaxis of Cisplatin-Induced Emesis. J. Clin. Oncol. 13:1242-
`1248, 1995.
`
`46. Navari, R.M., Madajewicz, S., Anderson, N. et al.: Oral Ondansetron for the Control of
`Cisplatin Induced Delayed Emesis: A Large, Multi -Center, Double Blind, Randomized
`Comparative Trial of Ondansetron Versus Placebo.
`J. Clin. Oncol. 13: 2408-16, 1995.
`
`47. Navari, R.M.: Is Oral Ondansetron Really Efficacious in the control of Cis -Platinum -
`Induced Delayed Emesis?
`J. Clin Oncol. 14: 1401-2, 1996
`
`48. Miller, A.A., Lipton, A., Henderson, I.C., Navari, R.M., et al: Fadrozole Hydrochloride in
`Postmenopausal Patients with Metastatic Breast Carcinoma. Cancer 78: 789-93, 1996.
`
`49. Hesketh, P., Navari, R.M., Grote, T., et al: Double-Blind, Randomized Comparison of the
`Antiemetic Efficacy of Intravenous Dolasetron Mesylate and Intravenous Ondansetron in the
`Prevention of Acute Cisplatin-Induced Emesis in Patients With Cancer. J. Clin. Oncol. 14:
`2242-2249, 1996.
`
`50. Pater, J.L., Lofters, W.S., Zee, B., Dempsey, E., Walde, D., Moquin, J.P., Wilson, K.,
`Hoskins, P., Guevin, R.M., Verma, S. Navari, R.M., et al: The Role of the 5-HT
`3 Antagonists
`Ondansetron and Dolasetron in the Control of Delayed Onset Nausea and Vomiting in
`Patients Receiving Moderately Emetogenic Chemotherapy. Ann. Oncol. 8: 181-85, 1997.
`
`51. Perez, E.A., Navari, R.M., Kaplan, H.G., et al: Efficacy and Safety of Different Doses of
`Granisetron for the Prophylaxis of Cisplatin-Induced Emesis. Support Care Cancer 5: 31-37,
`1997.
`
`52. Kris, M.G., Pendergrass, K.B., Navari, R.M., et al: Prevention of Acute Emesis Following
`High-Dose Cisplatin with the Combination of Oral Dolasetron and Dexamethasone. J. Clin.
`Oncol., 15:2135-38, 1997.
`
`53. Beck TM, York M, Chang A, Navari RM, et al: Oral Ondansetron 8 mg Twice Daily Is as
`Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated
`with Moderately Emetogenic Cancer Chemotherapy. Cancer Invest. 15:297-303, 1997.
`
`54. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin J, Wilson K, Hoskins P, Guevin
`RM, Verma S, Navari RM, et al: Phase III Double- Blind Comparison of Dolasetron
`Mesylate and Ondansetron and an evaluation of the Additive Role of Dexamethasone in the
`Prevention of Acute and Delayed Nausea and Vomiting Due to Moderately Emetogenic
`Page 11 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 12
`
`Chemotherapy. J. Clin. Oncol. 15:2966-73, 1997.
`
`55. Gralla R.J., Navari R.M., Hesketh P.J., et al. Single-Dose Oral Granisetron Has Equivalent
`Antiemetic Efficacy to Intravenous Ondansetron for Highly Emetogenic Cisplatin- Based
`Chemotherapy. J. Clin Oncol. 16:1568-1573, 1998.
`
`56. Navari RM. The Role of Neurokinin-1 Antagonists in Reducing Chemotherapy Induced
`Emesis: Current Status. Current Advances in Emesis Control, September, 1998.
`
`57. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a
`neurokinin-1 receptor antagonist. N. Engl. J. Med. 340: 190-5, 1999.
`
`58. Navari RM, Carides AD, Gertz BJ Prevention of cisplatin-induced emesis by a neurokinin-1
`receptor antagonist. N.Engl. J. Med. 340: 1926-7, 1999.
`
`59. Navari RM. Use of placebos in delayed-emesis studies. J. Clin. Oncol. 17:1648-9, 1999.
`
`60. Navari RM, Horner-Catt J, Siegler M. A prisoner with chronic myelogenous leukemia.
` Bone Marrow Transplantation, 24:1037-39, 1999.
`
`61. Navari RM, Stocking CA, Siegler M. Patient Decisions Concerning Palliative Care.
`Proceedings of the Xth International Association of Catholic Medical Schools Congress,
`J. Cousins, ed., Lille, France, 2000.
`
`62. Navari RM, Stocking CA, Siegler M. Preferences of Patients With Advanced Cancer
`for Hospice Care. JAMA 284:2449, 2000.
`
`63. Anderson AK, Nemecek JE, Navari RM. International Study in Premedical Education.
` Academic Medicine, 76: 1158, 2001.
`
`64. Harris L, Batist G, Belt R, Rovira D, Navari R, Garrett T, Azarnia N, Welles L. Winer E.
`Liposome-encapsulated Doxorubicin Compared to Conventional Doxorubicin in a
`Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Cancer. Cancer,
`87: 25-33, 2002.
`
`65. Navari RM. Physicians Tackle Ethical Issues in Palliative Care. Oncologistics, 1:17, 2002.
`
`66. Van Belle S, Lichinitser MR, Navari RM, et. al. Prevention of Cisplatin-Induced Acute and
` Delayed Emesis by the Selective Neurokinin-1 Antagonists, L-758,298 and MK-869.
` Cancer 94:3032-41, 2002.
`
`67. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis:
`Page 12 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 13
`
` preclinical data. Current Advances in Emesis Control 2:3-6, 2002.
`
`68. White PH, Kuhlenschmidt, HL, Vancura BG, Navari RM. Antimicrobial use in patients with
` advanced cancer receiving hospice care. J Pain Symptom Management, 25: 438-443, 2003.
`
`69. Navari RM. Infections in Patients with Advanced Cancer. in Handbook of
` Advanced Cancer, MJ Fisch, E Bruera (eds), pp. 444-459, Cambridge University Press,
` New York, 2003.
`
`70. Navari RM, Koeller JM. Electrocardiographic Effects of the 5-Hydroxytryptamine-3
` Receptor Anatogonists. Annals of Pharmacotherapy, 37: 1276-1286, 2003.
`
`71. Navari RM. Caring for patients with chemotherapy-induced nausea and vomiting: a paradigm
` shift in treatment options. SCAN 3: 2-17, 2003.
`
`72. Navari RM. Chemotherapy-induced nausea and vomiting: New treatment options.
` Contemporary Oncology 2: 1-10, 2003.
`
`73. Navari RM. Pathogenesis based treatment of chemotherapy-induced nausea and vomiting:
` Two new agents. J Supportive Oncology, 1: 89-103, 2003.
`
`74. Navari RM, Koeller JM. Cardiovascular effects of the 5-Hydroxytryptamine-3 receptor
` antagonists. Annals of Pharmacotherapy 37: 1918-19, 2003.
`
`75. Navari RM "Inhibiting substance P pathway for prevention of chemotherapy-induced emesis:
` Preclinical data, clinical trials of neurokinin-1 receptor antagonists" in Supportive Cancer
` Therapy 2004; 1:89-96.
`
`76. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis:
` summary of clinical trials. Cancer Investigation 22: 569-576, 2004.
`
`77. Passik S, Navari RM, Loehrer PJ et al. A phase I trial of olanzapine (Zyprexa) for
` the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer
` Investigation, 22: 383-388, 2004.
`
`78. Suckow MA, Gutierrez LS, Risatti CA, Wolter WR, Taylor RE, Pollard M, Navari RM,
` Castellino FJ, Paoni NF The anti-ischemic agent ranolazine promotes the development of
` intestinal tumors in APC Min Mice, Cancer Letters, 209: 165-169, 2004.
`
`79. Navari RM Aprepitant – A neurokinin-1 receptor antagonist for the treatment of
` chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4:715-724, 2004.
`
`Page 13 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 14
`
`80. Navari RM, Einhorn LH, Passik SD et al. A phase II trial of olanzapine for the
`prevention of chemotherapy induced nausea and vomiting. Supportive Care Cancer,
` 13: 529 - 534, 2005.
`
`81. Navari RM Advances in the treatment of chemotherapy-induced nausea and vomiting.
` Hospital Pharmacy Europe, 20: 37-40, 2005.
`
`82. Reinbolt RE, Shenk AM, White PH, Navari RM. Symptomatic Treatment of Infections in
` Patients with Advanced Cancer Receiving Hospice Care. J Pain Symptom Management,
` 30: 175-182, 2005.
`
`83. Navari RM. Treating depression in people with cancer. Coping, November/December: 8-9,
` 2005.
`
`84. Navari RM, Province PS. Emerging Drugs for Chemotherapy-induced Emesis. Expert
` Opin Emerging Drugs, 11:137-151, 2006.
`
`
`85. Busquets
` L, Guillen H, DeFord ME, Suckow MA, Navari RM, Castellino FJ, Prorok M
` Cathepsin E is a Specific Marker of Dysplasia in APCMin/+ Mouse Intestine. Tumor Biol
` 27: 36-42, 2006.
`
`86. Navari, RM Ondansetron, prochlorperazine, and dexamethasone have similar effects on
` prevention of delayed chemotherapy-induced nausea and vomiting- commentary.
` Cancer Treatment Reviews 32 (1): 50-54, 2006.
`
`87.Province PS, Navari RM Infections. Chapter 79, in Textbook of Palliative
` Medicine E Bruera, IJ Higginson, C Ripamonti, CF von Gunten (eds), Arnold
` Publishers, London, 2006.
`
`88. Navari RM Palonosetron: A second generation 5-Hydroxytryptamine 3 (5-HT3) receptor
` antagonist. Future Oncology, 2: 591-602, 2006.
`
`89. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced
` nausea and vomiting: From neuropharmacology to clinical investigations. Cancer J 12: 342-
` 348, 2006.
`
`90. Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. JNCCN,
` 5: 51-59, 2007.
`
`91. Navari RM. Review of Updated Antiemetic Guidelines for Chemotherapy-Induced Nausea
` and Vomiting. Community Oncology, 4: 1s-11s, 2007.
`Page 14 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 15
`
`
`92. Navari RM, Einhorn LH, Loehrer PJ et al. A phase II trial of olanzapine,
` dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea
` and vomiting. Supportive Care Cancer, 15: 1285 - 1291, 2007.
`
`93. Navari RM End of life decisions by adults with cancer: Role of religious practices
`and
` spiritual beliefs. in “Faith and Healing”, T. Merluzzi, NC Hvidt (eds), in press, 2008.
`
`94. Navari, RM Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the
` prevention of chemotherapy induced nausea and vomiting. Expert Opin Invest Drugs,
` 16: 1977-1985, 2007.
`
`95. Navari RM, Brenner MC, Wilson MN Treatment of depressive symptoms in patients
` with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat
` 112: 197-201, 2008.
`
`96. Navari RM Casopitant: drug profile. The Investigational Drugs Database: Drug
` Report www.iddb3.com, July, 2008.
`
`97. Navari RM Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and
` antinausea activities. Curr Opin Investig Drugs, 9: 774-785, 2008.
`
`98. Navari RM Fosaprepitant for the prevention of chemotherapy induced nausea and
` Vomiting. . Expert Rev Anticancer Ther 8: 1733-1742, 2008.
`
`99. Navari RM Prevention and treatment of chemotherapy-induced nausea and vomiting
` in the setting of moderately emetogenic chemotherapy.
` www.medscape.com/viewprogram/17173
`, August, 2008.
`
`100. Navari RM Antiemetic control:Toward a new standard of care for emetogenic
` chemotherapy. Expert Rev Pharmacotherapy 10: 629-644, 2009.
`
`101. Navari RM Pharmacological management of chemotherapy-induced nausea and
` vomiting. Drugs 69: 515-533, 2009.
`
`102. Navari RM Palonosetron: a second generation 5-Hydroxytryptamine-3 receptor
` antagonist. Expert Opin Drug Metabolism Toxicity 5: 1577-1586, 2009.
`
`103. Navari RM Current treatment options for managing chemotherapy-induced nausea
` and vomiting (CINV). Contemporary Oncology 1:39-47, 2009.
`
`Page 15 of 40
`
`
`
`
`
`
`
`CURRICULUM VITAE
`Rudolph Modesto Navari, M.D.
`Page 16
`
`104. Navari, RM Brenner MC Treatment of cancer-related anorexia with megestrol
` acetate and olanzapine. Support Care Cancer, 18:951-956, 2010.
`
`105. Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and
` vomiting. Cancer Management Res. 1:167-176, 2009.
`
`106. Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and
` vomiting in patients with cancer. Future Oncology, 6:1073-84, 2010.
`
`107. Castellino FJ, Donahue DL, Navari RM et al. An accompanying genetic severe
` deficiency of tissue factor protects mice with a protein C deficiency from lethal
` endotoxemia. Blood, 117: 283-289, 2011.
`
`108. Navari RM, Province PS, Passik, SD Management of Nausea and Vomiting in Cancer Patients.
` in Cancer Management in Man: Biological Response Modifiers, Chemotherapy, Biological
` therapy, Hyperthermia, and Supporting Measures B Minev, (ed.), pp 453-71, Springer
` Academic Publishers, N.Y., 2011.
`
`109. Navari RM, Gray SE, Kerr AC Olanzapine versus aprepitant for the prevention of
` chemotherapy induced nausea and vomiting (CINV): A randomized phase III trial.
` J Supp Oncol, 9: 188-195, 2011.
`
`110. Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz, Swearingen A,
` Navari RM, Ploplis V, Castellino FJ. Blood component therapy in trauma guided with the
` Utilization of the perfusionist and thromboelastography. J ExtraCorporeal Technology,
` 43: 162-67, 2011.
`
`111. Navari RM Treatment of Chemotherapy Induced Nausea. Community Oncology, 9: 20-26,
` 2012.
`
`112. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA,
` Navari RM, Bilgicer B. VLA4 targeting multifunctional nanoparticles overcome drug
` Resistance and inhibit tumor growth in multiple myeloma. Blood Cancer J, 2: 64-69, 2012.
`
`113. Navari RM How do I treat chemotherapy-induced nausea and vomiting? Oncology Times,
` 34: 16-19, 2012.
`
`114. Navari RM, Nagy, CK, Gray SE. The use of olanzapine versus metoclopramide for the
`